GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response-Reference-Cited by-同舟云学术

GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

Published:2010-10 Issue:1 Volume:137 Page:31-40
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Chéramy Mikael,Skoglund Camilla,Johansson Ingela,Ludvigsson Johnny,Hampe Christiane S.,Casas Rosaura

Funder

Swedish Research Council

Swedish Child Diabetes Foundation (Barndiabetesfonden)

Medical Research Council of Southeast Sweden

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference35 articles.

1. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10;Karlsen;Proc. Natl Acad. Sci. USA,1991

2. Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512);Payton;J. Clin. Invest.,1995

3. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus;Seissler;J. Clin. Invest.,1993

4. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes;Borg;Acta Paediatr.,2000

5. Autoantibodies associated with type I diabetes mellitus persist after diagnosis in children;Savola;Diabetologia,1998

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GABA and Combined GABA with GAD65-Alum Treatment Alters Th1 Cytokine Responses of PBMCs from Children with Recent-Onset Type 1 Diabetes;Biomedicines;2023-07-10

2. Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives;International Journal of Molecular Sciences;2022-04-24

3. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial);Acta Diabetologica;2022-01-31

4. Immune response differs between intralymphatic or subcutaneous administration of GAD‐alum in individuals with recent onset type 1 diabetes;Diabetes/Metabolism Research and Reviews;2021-10-12

5. Novel delivery mechanisms for antigen-specific immunotherapy;Current Opinion in Endocrinology, Diabetes & Obesity;2021-06-07